Publications by authors named "J Ahnert"

Introduction: Following rehabilitation, patients are often unable to continue with the behavioral changes they had learned there in the long term. It is therefore important to offer aftercare services to improve self-management. Internet-based and telephone aftercare concepts in particular are low-cost and flexible in application, and offer an opportunity to significantly increase the use of aftercare measures.

View Article and Find Full Text PDF

Targeting actionable fusions has emerged as a promising approach to cancer treatment. Next-generation sequencing (NGS)-based techniques have unveiled the landscape of actionable fusions in cancer. However, these approaches remain insufficient to provide optimal treatment options for patients with cancer.

View Article and Find Full Text PDF
Article Synopsis
  • Sapanisertib, a dual mTORC1/2 inhibitor, was combined with ziv-aflibercept, an anti-VEGF treatment, in a Phase 1 study to assess its safety and effectiveness in patients with advanced solid tumors.
  • Fifty-five heavily pre-treated patients participated, with the treatment showing a maximum tolerated dose of sapanisertib and ziv-aflibercept resulting in notable side effects like hypertension and fatigue but no severe (grade 5) complications.
  • The combination therapy showed promising anti-tumor activity, with 74% of patients achieving stable disease and an overall disease control rate of 78%.
View Article and Find Full Text PDF

Introduction: Genomic profiling is performed in patients with advanced or metastatic cancer, in order to direct cancer treatment, often sequencing tumor-only, without a matched germline comparator. However, because many of the genes analyzed on tumor profiling overlap with those known to be associated with hereditary cancer predisposition syndromes (HCPS), tumor-only profiling can unknowingly uncover germline pathogenic (P) and likely pathogenic variants (LPV). In this study, we evaluated the number of patients with P/LPVs identified in and () via tumor-only profiling, then determined the germline testing outcomes for those patients.

View Article and Find Full Text PDF